The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence

Jie Jiang; Xiaoxia Tang; Yongzhu Pu; Yong Yang; Conghui Yang; Fake Yang; Yadong Tian; Jindan Li; Hua Sun; Sheng Zhao; Long Chen

doi:10.3389/fendo.2022.897513

The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence

Front Endocrinol (Lausanne). 2022 May 27:13:897513. doi: 10.3389/fendo.2022.897513. eCollection 2022.

Authors

Jie Jiang¹, Xiaoxia Tang², Yongzhu Pu¹, Yong Yang³, Conghui Yang¹, Fake Yang¹, Yadong Tian¹, Jindan Li¹, Hua Sun¹, Sheng Zhao¹, Long Chen¹

Affiliations

¹ Department of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, China.
² Department of Pharmacy, The Second Affiliated Hospital of Kunming Medical University, Yunnan, China.
³ Department of Urology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, China.

Abstract

Prostate cancer (PCa) induced death is the predominant cause of cancer-related death among men in 48 countries. After radical treatment, biochemical recurrence has become an important factor for prognosis. The early detection and diagnosis of recurrent lesions are very helpful in guiding treatment and improving the prognosis. PET/CT is a promising method for early detection of lesions in patients with biochemical recurrence of prostate cancer. This article reviews the progress of the research on PET/CT in the PCa biochemical recurrence and aims to introduce new technologies and provide more direction for future research.

Keywords: PET/CT- Positron Emission Tomography Computed Tomography; biochemical recurrence; imaging; prostate cancer.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Male
Positron Emission Tomography Computed Tomography* / methods
Prognosis
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology